Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX) vaccination in patients with INOPERABLE metastatic colorectal cancer.

Next Previous
Trial Profile

A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX) vaccination in patients with INOPERABLE metastatic colorectal cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 5T4 (Primary) ; Cyclophosphamide
  • Indications Colorectal cancer
  • Focus Pharmacodynamics
  • Acronyms TaCTiCC

Most Recent Events

  • 17 Mar 2017 Results have been published in an Oxford BioMedica financial report.
  • 17 Mar 2017 According to an Oxford BioMedica media release, data from the study has been presented in a oster at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer (ASCO-SITC) symposium.
  • 15 Apr 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top